Search

Your search keyword '"and, Ling"' showing total 4,147 results
Start Over Author "and, Ling" Journal blood
4,147 results on '"and, Ling"'

1. The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Author

Fei, Ming-Yue, Wang, Yong, Chang, Bin-He, Xue, Kai, Dong, Fangyi, Huang, Dan, Li, Xi-Ya, Li, Zi-Juan, Hu, Cheng-Long, Liu, Ping, Wu, Ji-Chuan, Yu, Peng-Cheng, Hong, Ming-Hua, Chen, Shu-Bei, Xu, Chun-Hui, Chen, Bing-Yi, Jiang, Yi-Lun, Liu, Na, Zhao, Chong, Jin, Jia-Cheng, Hou, Dan, Chen, Xin-Chi, Ren, Yi-Yi, Deng, Chu-Han, Zhang, Jia-Ying, Zong, Li-juan, Wang, Rou-Jia, Gao, Fei-Fei, Liu, Hui, Zhang, Qun-Ling, Wu, Ling-Yun, Yan, Jinsong, Shen, Shuhong, Chang, Chun-Kang, Sun, Xiao-Jian, and Wang, Lan

Published
2023
Full Text
View/download PDF

2. A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Author

Murtadha, Mariam, Park, Miso, Zhu, Yinghui, Caserta, Enrico, Napolitano, Ottavio, Tandoh, Theophilus, Moloudizargari, Milad, Pozhitkov, Alex, Singer, Mahmoud, Dona, Ada Alice, Vahed, Hawa, Gonzalez, Asaul, Ly, Kevin, Ouyang, Ching, Sanchez, James F., Nigam, Lokesh, Duplan, Amanda, Chowdhury, Arnab, Ghoda, Lucy, Li, Ling, Zhang, Bin, Krishnan, Amrita, Marcucci, Guido, Williams, John C., and Pichiorri, Flavia

Published
2024
Full Text
View/download PDF

4. A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy

Author

Zhang, Xiaoshuai, Liu, Bingcheng, Huang, Jian, Zhang, Yanli, Xu, Na, Gale, Robert Peter, Li, Weiming, Liu, Xiaoli, Zhu, Huanling, Pan, Ling, Yang, Yunfan, Lin, Hai, Du, Xin, Liang, Rong, Chen, Chunyan, Wang, Xiaodong, Li, Guohui, Liu, Zhuogang, Zhang, Yanqing, Liu, Zhenfang, Hu, Jianda, Liu, Chunshui, Li, Fei, Yang, Wei, Meng, Li, Han, Yanqiu, Lin, Li’e, Zhao, Zhenyu, Tu, Chuanqing, Zheng, Caifeng, Bai, Yanliang, Zhou, Zeping, Chen, Suning, Qiu, Huiying, Yang, Lijie, Sun, Xiuli, Sun, Hui, Zhou, Li, Liu, Zelin, Wang, Danyu, Guo, Jianxin, Pang, Liping, Zeng, Qingshu, Suo, Xiaohui, Zhang, Weihua, Zheng, Yuanjun, Huang, Xiaojun, and Jiang, Qian

Published
2024
Full Text
View/download PDF

5. Loss of function of ENT3 drives histiocytosis and inflammation through TLR-MAPK signaling

Author

Shiloh, Ruth, Lubin, Ruth, David, Odeya, Geron, Ifat, Okon, Elimelech, Hazan, Idit, Zaliova, Marketa, Amarilyo, Gil, Birger, Yehudit, Borovitz, Yael, Brik, Dafna, Broides, Arnon, Cohen-Kedar, Sarit, Harel, Liora, Kristal, Eyal, Kozlova, Daria, Ling, Galina, Shapira Rootman, Mika, Shefer Averbuch, Noa, Spielman, Shiri, Trka, Jan, Izraeli, Shai, Yona, Simon, and Elitzur, Sarah

Published
2023
Full Text
View/download PDF

7. Patients with Asian-type DEL can safely be transfused with RhD-positive blood

Author

Ji, Yanli, Luo, Yalin, Wen, Jizhi, Sun, Yuanfan, Jia, Shuangshuang, Ou, Chunquan, Yang, Wenbing, Chen, Jingwang, Ye, Hanshen, Liu, Xiangfu, Liang, Yongneng, Lu, Zhigang, Feng, Ying, Wu, Xinzhong, Xiao, Muzhou, Mo, Jiankun, Zhou, Zhenhai, Wang, Zhen, Liao, Zhijian, Chen, Junhu, Wei, Ling, Luo, Guangping, Santoso, Sentot, Fichou, Yann, Flegel, Willy Albert, Shao, Chaopeng, Li, Chengyao, Zhang, Rui, and Fu, Yongshui

Published
2023
Full Text
View/download PDF

8. Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia

Author

Chen, Yun, Choi, Michael Y, Chen, Liguang, Yu, Jian, Zhang, Ling, Ghia, Emanuela M, Sanchez-Lopez, Elsa, Widhopf II, George F, Messer, Karen, Rassenti, Laura Z, Jamieson, Catriona, and Kipps, Thomas J

Subjects
Clinical Research, Hematology, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

Abstract ROR1 is an oncoembryonic receptor tyrosine kinase expressed on chronic lymphocytic leukemia (CLL) B cells, but not on most normal post-partum tissues. It functions as a receptor for Wnt5a, which is present at high levels in the plasma of patients with CLL relative to that of age-matched controls. Wnt5a/ROR1 is known to activate pro-survival signals in CLL cells, but detailed mechanisms are not fully understood. We found that monocyte-derived Nurse-Like Cells (NLC) could induce CLL cells to activate STAT3 (pY705) and that this effect could be blocked by neutralizing antibodies to Wnt5a, which we found expressed at high levels by NLC. We observed that this effect also could be blocked by cirmtuzumab, a humanized mAb that can inhibit ROR1-signaling, indicating this effect of NLC on CLL cells was Wnt5a and ROR1 dependent. We performed a time-course study examining for pSTAT3 in isolated serum-starved CLL cells treated with exogenous Wnt5a. This revealed that Wnt5a induced delayed activation of STAT3, appearing first at 3 hours. As such, we hypothesized that the noted activation of STAT3 in CLL cells was indirect, being caused by a factor(s) made by isolated CLL cells in response to Wnt5a. We examined harvested supernatants of CLL cells cultured with or without Wnt5a using a human cytokine array assay. Multiple proinflammatory factors including IL-6, IL-8, CCL2, CCL3, CCL4, and CXCL1 were detected in the medium of CLL cells cultured for 24 hours with Wnt5a that were either not detected or found at lower levels in the medium of CLL cells cultured without Wnt5a. Moreover, the medium harvested from CLL cells cultured with Wnt5a, but not the medium of CLL cells cultured without, could induce pSTAT3 within 30 minutes in serum-starved CLL cells; this effect could be inhibited by the anti-IL-6-receptor mAb, tocilizumab, but not by cirmtuzumab, even when used at concentrations that could block the capacity of Wnt5a to induce latent activation of STAT3 and production of IL-6. Since the genes encoding these proinflammatory factors are targets of nuclear factor kappa B (NF-κB), we hypothesized that they were induced through Wnt5a/ROR1-dependent activation of NF-κB. Consistent with this notion, we found that BAY 11-7082 or BMS-345541, which can each inhibit activation of NF-κB, also could block Wnt5a-induced CLL-cell activation of STAT3 and production of IL-6. Furthermore, Wnt5a could induce phosphorylation of NF-κB p65 in CLL cells within 30 minutes, and this effect could be blocked by cirmtuzumab. Using real-time PCR array to evaluate for expression of NF-κB target genes, we found Wnt5s could induce up-regulation of NF-κB target genes in CLL cells, and that this effect could be blocked by cirmtuzumab. Moreover, these studies revealed that Wnt5a/ROR1/NF-κB signaling could induce expression of genes encoding the noted proinflammatory factors in CLL cells. To examine the in vivo significance of these findings, we collected plasma and CLL cells from patients treated with cirmtuzumab in a phase I clinical trial (Choi, MY, et al, Cell Stem Cell 22:951, 2018). RNAseq and ELISA respectively were used to examine the transcriptomes of negatively-selected CLL cells and the concentrations of IL-6 in plasma collected before and after treatment. Consistent with our in vitro findings, treatment with cirmtuzumab downregulated CLL-cell expression of NF-κB target genes in vivo by gene set enrichment analysis (n = 3, NES = 2.10, FDR q = 0.01). The levels of IL-6 in plasma also were significantly decreased in patients after therapy (p = 0.02, n = 5, Paired Student t test). Collectively, these studies indicate that Wnt5a/ROR1-dependent signaling induced by NLC may play a major role in the noted activation of NF-κB in CLL, leading to the production of factors, such as IL-6, which are posted to contribute to pathogenesis. Moreover, these data suggest that some of the noted clinical effects of therapy with cirmtuzumab may be due to suppression of Wnt5a-induced, ROR1-dependent activation of NF-κB in patients with CLL. Disclosures Choi: Genentech: Speakers Bureau; Pharmacyclics: Consultancy, Research Funding, Speakers Bureau; Gilead: Speakers Bureau; AbbVie, Inc: Consultancy, Speakers Bureau; Rigel: Consultancy. Kipps:AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Verastem: Membership on an entity's Board of Directors or advisory committees; Verastem: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech Inc: Consultancy, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy; F. Hoffmann-La Roche Ltd: Consultancy, Research Funding.

Published
2018

11. Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade

Author

Wang, Hanying, He, Xin, Zhang, Lei, Dong, Haojie, Huang, Feiteng, Xian, Jie, Li, Min, Chen, Wei, Lu, Xiyuan, Pathak, Khyatiben V., Huang, Wenfeng, Li, Zheng, Zhang, Lianjun, Nguyen, Le Xuan Truong, Yang, Lu, Feng, Lifeng, Gordon, David J., Zhang, Jing, Pirrotte, Patrick, Chen, Chun-Wei, Salhotra, Amandeep, Kuo, Ya-Huei, Horne, David, Marcucci, Guido, Sykes, David B., Tiziani, Stefano, Jin, Hongchuan, Wang, Xian, and Li, Ling

Published
2022
Full Text
View/download PDF

12. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia

Author

Goswami, Swagata, Mani, Rajeswaran, Nunes, Jessica, Chiang, Chi-Ling, Zapolnik, Kevan, Hu, Eileen, Frissora, Frank, Mo, Xiaokui, Walker, Logan A., Yan, Pearlly, Bundschuh, Ralf, Beaver, Larry, Devine, Raymond, Tsai, Yo-Ting, Ventura, Ann, Xie, Zhiliang, Chen, Min, Lapalombella, Rosa, Walker, Alison, Mims, Alice, Larkin, Karilyn, Grieselhuber, Nicole, Bennett, Chad, Phelps, Mitch, Hertlein, Erin, Behbehani, Gregory, Vasu, Sumithira, Byrd, John C., and Muthusamy, Natarajan

Published
2022
Full Text
View/download PDF

18. Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study

Author

Chang, Hong, primary, Pan, Ling, additional, Jia, Yongqian, additional, Xiang, Bing, additional, Huang, Xiaoou, additional, Guo, Yong, additional, Li, Meng, additional, Xing, Hongyun, additional, Xu, Fang, additional, Yuan, Ying, additional, Lian, Ying, additional, Yang, Lihua, additional, and Niu, Ting, additional

Published
2023
Full Text
View/download PDF

22. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia

Author

Zhu, Yinghui, He, Xin, Lin, Yi-Chun, Dong, Haojie, Zhang, Lei, Chen, Xianwei, Wang, Zhihao, Shen, Yudao, Li, Min, Wang, Hanying, Sun, Jie, Nguyen, Le Xuan, Zhang, Han, Jiang, Wenjuan, Yang, Yanzhong, Chen, Jianjun, Müschen, Markus, Chen, Chun-Wei, Konopleva, Marina Y., Sun, Weili, Jin, Jian, Carlesso, Nadia, Marcucci, Guido, Luo, Yun, and Li, Ling

Published
2019
Full Text
View/download PDF

25. PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia

Author

He, Xin, Zhu, Yinghui, Lin, Yi-Chun, Li, Min, Du, Juan, Dong, Haojie, Sun, Jie, Zhu, Lei, Wang, Hanying, Ding, Zonghui, Zhang, Lei, Zhang, Lianjun, Zhao, Dandan, Wang, Zhihao, Wu, Herman, Zhang, Han, Jiang, Wenjuan, Xu, Yang, Jin, Jian, Shen, Yudao, Perry, Jeff, Zhao, Xinyang, Zhang, Bin, Liu, Songbai, Xue, Sheng-Li, Shen, Binghui, Chen, Chun-Wei, Chen, Jianjun, Khaled, Samer, Kuo, Ya-Huei, Marcucci, Guido, Luo, Yun, and Li, Ling

Published
2019
Full Text
View/download PDF

27. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation

Author

Jacquelin, Sebastien, Straube, Jasmin, Cooper, Leanne, Vu, Therese, Song, Axia, Bywater, Megan, Baxter, Eva, Heidecker, Matthew, Wackrow, Brad, Porter, Amy, Ling, Victoria, Green, Joanne, Austin, Rebecca, Kazakoff, Stephen, Waddell, Nicola, Hesson, Luke B., Pimanda, John E., Stegelmann, Frank, Bullinger, Lars, Döhner, Konstanze, Rampal, Raajit K., Heckl, Dirk, Hill, Geoffrey R., and Lane, Steven W.

Published
2018
Full Text
View/download PDF

32. Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Author

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, and Qian Jiang

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

33. Human T-cell leukemia virus type 2 produces a spliced antisense transcript encoding a protein that lacks a classic bZIP domain but still inhibits Tax2-mediated transcription

Author

Halin, Marilène, Douceron, Estelle, Clerc, Isabelle, Journo, Chloé, Ko, Nga Ling, Landry, Sébastien, Murphy, Edward L, Gessain, Antoine, Lemasson, Isabelle, Mesnard, Jean-Michel, Barbeau, Benoît, and Mahieux, Renaud

Subjects
Cancer, Genetics, Rare Diseases, Human Genome, Hematology, Aetiology, 2.2 Factors relating to the physical environment, 2.1 Biological and endogenous factors, Adult, Aged, Aged, 80 and over, Base Sequence, Basic-Leucine Zipper Transcription Factors, Blotting, Northern, Blotting, Western, Female, Fluorescent Antibody Technique, Gene Expression Regulation, Viral, Gene Products, tax, Human T-lymphotropic virus 2, Humans, Immunoenzyme Techniques, Immunoprecipitation, Jurkat Cells, Luciferases, Middle Aged, Molecular Sequence Data, Promoter Regions, Genetic, RNA Splicing, RNA, Antisense, RNA, Messenger, Reverse Transcriptase Polymerase Chain Reaction, Sequence Homology, Nucleic Acid, Transcription, Genetic, Transfection, Viral Proteins, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology
Abstract

Human T-cell leukemia virus type 1 (HTLV-1) and type 2 (HTLV-2) retroviruses infect T lymphocytes. The minus strand of the HTLV-1 genome encodes HBZ, a protein that could play a role in the development of leukemia in infected patients. Herein, we demonstrate that the complementary strand of the HTLV-2 genome also encodes a protein that we named APH-2 for "antisense protein of HTLV-2." APH-2 mRNA is spliced, polyadenylated, and initiates in the 3'-long terminal repeat at different positions. This transcript was detected in all HTLV-2-infected cell lines and short-term culture of lymphocytes obtained from HTLV-2 African patients tested and in 4 of 15 HTLV-2-infected blood donors. The APH-2 protein is 183 amino acids long, is localized in the cell nucleus, and is detected in vivo. Despite the lack of a consensus basic leucine zipper domain, APH-2 interacts with cyclic adenosine monophosphate-response element binding protein (CREB) and represses Tax2-mediated transcription in Tax2-expressing cells and in cells transfected with an HTLV-2 molecular clone. Altogether, our results demonstrate the existence of an antisense strand-encoded protein in HTLV-2, which could represent an important player in the development of disorders, such as lymphocytosis, which is frequently observed in HTLV-2 patients.

Published
2009

37. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

Author

Michael D. Jain, Bachisio Ziccheddu, Caroline A. Coughlin, Rawan Faramand, Anthony J. Griswold, Kayla M. Reid, Meghan Menges, Yonghong Zhang, Ling Cen, Xuefeng Wang, Mohammad Hussaini, Ola Landgren, Marco L. Davila, Jonathan H. Schatz, Frederick L. Locke, and Francesco Maura

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Abstract

CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking immunotherapies approved for use against large B-cell lymphomas. Although host inflammatory and tumor microenvironmental markers associate with efficacy and resistance, the tumor-intrinsic alterations underlying these phenomena remain undefined. CD19 mutations associate with resistance but are uncommon, and most patients with relapsed disease retain expression of the wild-type receptor, implicating other genomic mechanisms. We therefore leveraged the comprehensive resolution of whole-genome sequencing to assess 51 tumor samples from 49 patients with CAR-19–treated large B-cell lymphoma. We found that the pretreatment presence of complex structural variants, APOBEC mutational signatures, and genomic damage from reactive oxygen species predict CAR-19 resistance. In addition, the recurrent 3p21.31 chromosomal deletion containing the RHOA tumor suppressor was strongly enriched in patients for whom CAR T-cell therapy failed. Pretreatment reduced expression or monoallelic loss of CD19 did not affect responses, suggesting CAR-19 therapy success and resistance are related to multiple mechanisms. Our study showed that tumor-intrinsic genomic alterations are key among the complex interplay of factors that underlie CAR-19 efficacy and resistance for large B-cell lymphomas.

Published
2022

38. Enhanced BNT162b2 vaccine-induced cellular immunity in anti-CD19 CAR T cell–treated patients

Author

Bernice Ling Zhi Oh, Nicole Tan, Ruklanthi de Alwis, Kamini Kunasegaran, Zhiwei Chen, Michelle Poon, Esther Chan, Jenny G. H. Low, Allen Eng Juh Yeoh, Antonio Bertoletti, and Nina Le Bert

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Abstract

Patients receiving CD19 CAR T-cell therapy for relapsed/refractory lymphoma experience prolonged and profound B-cell aplasia and hypogammaglobulinemia, placing them at a higher risk for severe COVID-19. Independently, Oh et al and Atanackovic et al demonstrate that despite attenuated humoral response to mRNA-based vaccines, patients demonstrate normal or heightened functional T-cell responses, including antiviral T-cell activity against SARS-CoV-2 variants including Omicron. Collectively, these data reinforce the importance of COVID-19 vaccination following CD19 CAR T-cell therapy, despite long-term B-cell aplasia.

Published
2022

39. Post-Transplantation Cyclophosphamide Combined with Tacrolimus and Low-Dose Post-Engraftment Anti-Thymoglobulin As Gvhd Prophylaxis for Patients Undergoing Peripheral Blood Stem Cell Transplantation from Haplo Donors: A Single Center Analysis

Author

Hu, Jiong, primary, GAO, Wenhui, additional, Chen, Ming, additional, Wang, Li-Ling, additional, Wang, Ling, additional, Devillier, Raynier, additional, Jiang, Jie-Ling, additional, and Blaise, Didier, additional

Published
2022
Full Text
View/download PDF

40. Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Author

Xue, Feng, primary, Zhou, Hu, additional, Chen, Yun, additional, Sun, Jing, additional, Zeng, Xiaojing, additional, Jin, Chenghao, additional, Lei, Pingchong, additional, Li, Zhenyu, additional, Xi, Yaming, additional, Sun, Lirong, additional, Cui, Zhongguang, additional, Zhao, Xielan, additional, Yang, Linhua, additional, Zhang, Bangshuo, additional, Shen, Aizong, additional, Wu, Runhui, additional, Wang, Xiaolin, additional, Liu, Ling, additional, Wang, Yuhua, additional, Sun, Lizhi, additional, Xia, Yan, additional, Mo, Weichuan, additional, Yuan, Dong, additional, Lou, Jiwei, additional, Gan, Taiping, additional, Hu, Chengli, additional, Ling, Chen, additional, Su, Hongsheng, additional, Wang, Yali, additional, Tang, Baolin, additional, and Yang, Renchi, additional

Published
2022
Full Text
View/download PDF

41. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

Author

Xu-Monette, Zijun Y., Li, Ling, Byrd, John C., Jabbar, Kausar J., Manyam, Ganiraju C., Maria de Winde, Charlotte, van den Brand, Michiel, Tzankov, Alexandar, Visco, Carlo, Wang, Jing, Dybkaer, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Richards, Kristy L., Hsi, Eric D., Choi, William W.L., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M., Møller, Michael B., Parsons, Ben M., Winter, Jane N., Wang, Michael, Hagemeister, Frederick B., Piris, Miguel A., Han van Krieken, J., Medeiros, L.Jeffrey, Li, Yong, van Spriel, Annemiek B., and Young, Ken H.

Published
2016
Full Text
View/download PDF

43. Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Author

Yumeng Zhang, Jennifer Eatrides, Ashley Rose, Ling Zhang, Farhad Khimani, Aleksandr Lazaryan, Bijal D. Shah, Hayder Saeed, Michael D. Jain, Hien D. Liu, Frederick L. Locke, Javier Pinilla Ibarz, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Lubomir Sokol, and Taiga Nishihori

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

44. Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Author

Jonathan Allen Webster, Madison C. Reed, Hua-Ling Tsai, Alexander J. Ambinder, Tania Jain, Amy E. DeZern, Mark J. Levis, Margaret M. Showel, Gabrielle T. Prince, Christopher S. Hourigan, Javier Bolaños-Meade, Lukasz P. Gondek, Gabriel Ghiaur, William Brian Dalton, Suman Paul, Ephraim J. Fuchs, Christian B. Gocke, Abbas Abbas Ali, Douglas E. Gladstone, Carol Ann Huff, Ivan M. Borrello, Lode J. Swinnen, Nina D. Wagner-Johnston, Richard F. Ambinder, Leo Luznik, Ivana Gojo, B. Douglas Douglas Smith, Ravi Varadhan, Richard J. Jones, and Philip H. Imus

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

45. Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Author

Sen Yang, Xiaoshuai Zhang, Yanli Zhang, Xin Du, Jianyu Weng, Huanling Zhu, Ling Pan, Yun-fan Yang, Li Meng, Zhenfang Liu, Xiaoli Liu, Na Xu, Chunyan Chen, Xiaodong WANG, Rong Liang, Jian Huang, Guohui Li, Chunshui Liu, Hai Lin, Jianda Hu, Li Fei, Bingcheng Liu, Weiming Li, Zhuogang Liu, Wei Yang, Xiao Jun Huang, and Qian Jiang

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

46. Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β-Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis

Author

Olivier Hermine, Maria Domenica Domenica Cappellini, Ali T. Taher, Thomas D. Coates, Vip Viprakasit, Antonis Kattamis, Jeevan K. Shetty, Marija Bosilkovska Weisskopf, Natalia Holot, Sadanand Vodala, Wen-Ling Kuo, and John B. Porter

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

47. Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity

Author

Haojie Dong, Xin He, Lei Zhang, Wei Chen, Yichun Lin, Songbai Liu, Huafeng Wang, Wenfeng Huang, Sierra Min Li, Yinghui Zhu, Dandan Zhao, Lucy Ghoda, Rui Su, Jianjun Chen, Ritin Sharma, Patrick Pirrotte, Xiwei Wu, Weidong Hu, Weidong Han, Binghui Shen, Ya-Huei Kuo, Jie Jin, Amandeep Salhotra, Jeffrey Wang, Guido Marcucci, Yun Luo, and Ling Li

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

48. TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion

Author

Yangchan Li, Xiaolan Deng, Lei Dong, Li Han, Le Xuan Truong Nguyen, Jianhuang Xue, Zhicong Zhao, Wei Li, Ying Qing, Chao Shen, Brandon Tan, Zhenhua Chen, Meilin Xue, Keith Leung, Kitty Wang, Srividya Swaminathan, Ling Li, Mark Wunderlich, James C Mulloy, Bin Zhang, David A Horne, Steve T Rosen, Guido Marcucci, Mingjiang Xu, Zejuan Li, Minjie Wei, Rui Su, and Jianjun Chen

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

49. A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Author

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, and Qian Jiang

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

50. Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML

Author

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Ling Zhang, Mohammad O Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew Kuykendall, Eric Padron, Alison R. Walker, Gail J. Roboz, Pinkal Desai, David A. Sallman, Kendra Sweet, Rami S. Komrokji, and Jeffrey E. Lancet

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

Catalog

Books, media, physical & digital resources
See catalog results